UnitedHealth Group stock gains 1.21 percent as Q3 test nears

Published on 10/07/2026 at 16:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UnitedHealth Group stock faces October 13 results after its Q2 medical care ratio fell to 86.7 percent. Adjusted EPS reached USD 6.38 against USD 4.08.

Pop-Art-Comic-Illustration eines fliegenden Arzt-Superhelden über Stadtsilhouette mit Halbtönen — UnitedHealth Group US91324P1021 als Pop-Art-Comic mit mutig fliegendem Arzt-Superhelden über farbenfroher Stadtsilhouette, Illustration mit AI erstellt.

UnitedHealth Group (ISIN US91324P1021) was trading at USD 380.89 on the NYSE on October 7, 2026 at 10:54 a.m. ET, up 1.21 percent from the USD 376.32 prior close. The October 13 earnings release now gives the stock its next major test.

Q3 must confirm cost improvement

According to Zacks on October 6, 2026, UnitedHealth's second-quarter medical care ratio improved to 86.7 percent from 89.4 percent a year earlier. The report identified the key question for the October 13 results as whether that improvement can continue after favorable reserve development of USD 860 million.

The second-quarter comparison also favored earnings. Adjusted EPS reached USD 6.38 versus USD 4.08 in the prior-year quarter, while operating earnings increased to USD 8.0 billion. The figures give the upcoming report a clear test: sustained medical-cost control must support the earnings recovery rather than rely on one-time reserve effects.

Medicare adds a second test

UnitedHealth's Medicare Advantage membership stood at 7.565 million at June 30, 2026, down 785,000 from a year earlier, according to Zacks. Management expects Medicare margins to finish 2026 above 3 percent, making enrollment quality and retention important indicators alongside the medical care ratio.

The company has also set a full-year medical care ratio outlook of 88.1 percent. That figure leaves the third quarter positioned between the improved Q2 result and the full-year target, so utilization and member mix will shape the market's reading of the report.

Consensus remains above the stock

Stock Analysis lists a Buy consensus from 26 analysts and an average 12-month price target of USD 481.72. That target lies 26.5 percent above the USD 380.89 price, while the stock remains below its 52-week high of USD 461.62 and above its low of USD 255.97.

For investors, the October 13 release must therefore answer two linked questions: whether the 86.7 percent medical care ratio was repeatable and whether Medicare profitability can improve alongside a smaller membership base.

UnitedHealth Group stock gains on October 7

UnitedHealth Group stock was trading at USD 380.89 on the NYSE on October 7, 2026 at 10:54 a.m. ET, with a market capitalization of USD 345.9 billion and volume of 821,416 shares.